乳腺癌组织多药耐药相关蛋白表达及其与化疗敏感性关系的研究  

Correlation between sensitiviy of neoadjuvant chemotherapy and multidrug-resistance in breast carcinoma

作　　者：孙勇[1] 袁凯[1] 付荣湛[1] 

机构地区：[1]山东大学附属千佛山医院普通外科,山东济南250014

出　　处：《中国现代普通外科进展》2008年第5期412-415,共4页Chinese Journal of Current Advances in General Surgery

摘　　要：目的:探讨3种耐药相关蛋白P-gp、GST-π和TopoⅡ在乳腺癌组织中的表达及其与乳腺癌新辅助化疗敏感性的相关性。方法:乳腺癌患者80例,随机分为应用新辅助化疗(CEF)组(A组)和未化疗组(B组),A组应用新辅助化疗2周期,化疗前后分别行B超检查测量肿瘤大小。采用S-P免疫组织化学法检测80例乳腺癌组织中P-gp、GST-π和TopoⅡ的表达情况。结果:P-gp的表达在A组较B组有显著升高(P<0.05);GST-π和TopoⅡ的表达在A组及B组的表达差异无统计学意义(P>0.05)。A组P-gp的表达情况与乳腺癌肿瘤的缩小呈直线相关(P<0.05);GST-π、TopoⅡ的表达情况与乳腺癌瘤体的缩小无明显相关(P>0.05)。P-gp的表达与腋窝淋巴结阳性有显著相关;GST-π的表达与肿瘤的分级有显著相关,与雌激素受体呈负相关;TopoⅡ的表达与肿瘤的分级呈正相关。结论:P-gp的表达可能与乳腺癌的获得性耐药有关,GST-π和TopoⅡ的表达可能与乳腺癌的天然耐药有关。Objective：To study the expressions of P-gp、GST-π、TopoⅡin breast carcinoma and the relationship between the drug resistance-associated proteins and the sensitivity of neoadjuvant chemotherapy of breast carcinoma.Methods：Eighty specimens of breast carcinoma were collected and the patients were classified randomly into group A and group B.Neoadjuvant chemotherapy（CEF）was used in group A,and we respectively measured maximum diameters of the tumors by B-ultrasound examination before and after the chemotherapy.we measured the expression of P-gp、GST-π、TopoⅡin 80 specimens by immunohistochemical technique（S-P）.Results：The expression of P-gp increased significantly in group A compared with group B（P〈0.05）.In group A,a significant linear correlation was observed between P-gp and the percentage of decrease of tumor（P〈0.05）.The expression of P-gp was significantly associated with positive axillary node.The expression of GST-π was significantly associated with the pathologic class of tumor,and a negative correlation was found between GST-πand ER.A positive correlation was found between TopoⅡand the pathologic class of tumor.Conclusions：P-gp perhaps has a close relationship with acquired resistance of breast carcinoma,GST-πand TopoⅡ perhaps have a close relationship with natural resistance of breast carcinoma.

关 键 词：多药耐药相关蛋白类 免疫组织化学 乳腺肿瘤 

分 类 号：R737.9[医药卫生—肿瘤]